Evidence map›Paper›PMID 35759080›Full record

ArticleCancer causes & control : CCC2022

Proceedings of the fifth international Molecular Pathological Epidemiology (MPE) meeting.

Song Yao, Peter T Campbell, Tomotaka Ugai, Gretchen Gierach, Mustapha Abubakar, Viktor Adalsteinsson, Jonas Almeida, Paul Brennan, Stephen Chanock, Todd Golub and 18 more

Abstract read
In one paragraph

Article in Cancer causes & control : CCC, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Song Yao *Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY, 14263, USA. song.yao@roswellpark.org.ORCID http://orcid.org/0000-0001-9442-1313
Peter T Campbell *Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Tomotaka Ugai *Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Gretchen Gierach *Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Mustapha AbubakarDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Viktor AdalsteinssonBroad Institute of MIT and Harvard, Boston, MA, USA.
Jonas AlmeidaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Paul BrennanInternational Agency for Research On Cancer (IARC/WHO), Genomic Epidemiology Branch, Lyon, France.
Stephen ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Todd GolubBroad Institute of MIT and Harvard, Boston, MA, USA.
Samir HanashDepartment of Clinical Cancer Prevention, MD Anderson Cancer Institute, Houston, TX, USA.
Curtis HarrisCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Cassandra A HathawayDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Karl KelseyDepartment of Epidemiology, Brown School of Public Health, Brown University, Providence, RI, USA.
Maria Teresa LandiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Faisal MahmoodDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Christina NewtonDepartment of Population Science, American Cancer Society, Atlanta, GA, USA.
John QuackenbushChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Scott RodigDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Nikolaus SchultzDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Guillermo TearneyDepartment of Pathology and Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA.
Shelley S TworogerDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Molin WangDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Xuehong ZhangChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Montserrat Garcia-Closas *Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Timothy R Rebbeck *Zhu Family Center for Global Cancer Prevention, Harvard T.H. Chan School of Public Health and Dana-Farber Cancer Institute, Boston, MA, USA.
Christine B Ambrosone *Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY, 14263, USA.
Shuji Ogino *Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. sogino@bwh.harvard.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang · 2002 to 2026
$57.4M
Precision Medicine of CancerZIABC011492 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HARRIS, CURTIS · 2013 to 2025
$23.2M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Life Course Cancer Epidemiology Cohort in WomenUM1CA176726 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2013 to 2017
$15.7M
The cBioPortal for Cancer GenomicsU24CA220457 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CERAMI, ETHAN, SANDER, CHRIS · 2017 to 2021
$6.4M
Unraveling the Complexities of Risk and Mechanism in CancerR35CA220523 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI QUACKENBUSH, JOHN · 2018 to 2024
$6.0M
Accelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0M
Immune epigenetic biomarkers of survival in glioma epidemiologyR01CA207360 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2017 to 2021
$3.8M
DNA-based Immune Phenotyping in HNSCC for Biomarkers of Response to ImmunotherapyR01CA253976 · NCI · BROWN UNIVERSITY · PI CHRISTENSEN, BROCK C, KELSEY, KARL TIMOTHY · 2021 to 2025
$3.3M
Cancer Research UK 27140NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA204749NCI NIH HHS R01 CA207360NCI NIH HHS R01 CA216265NCI NIH HHS R01 CA225947NCI NIH HHS R01 CA253976NCI NIH HHS R01 CA265742NCI NIH HHS R35 CA197735NCI NIH HHS R35 CA220523NCI NIH HHS U24 CA220457NCI NIH HHS U24 CA231846NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA186107World Health Organization 001
6 · The paper itself

Abstract

Cancer heterogeneities hold the key to a deeper understanding of cancer etiology and progression and the discovery of more precise cancer therapy. Modern pathological and molecular technologies offer a powerful set of tools to profile tumor heterogeneities at multiple levels in large patient populations, from DNA to RNA, protein and epigenetics, and from tumor tissues to tumor microenvironment and liquid biopsy. When coupled with well-validated epidemiologic methodology and well-characterized epidemiologic resources, the rich tumor pathological and molecular tumor information provide new research opportunities at an unprecedented breadth and depth. This is the research space where Molecular Pathological Epidemiology (MPE) emerged over a decade ago and has been thriving since then. As a truly multidisciplinary field, MPE embraces collaborations from diverse fields including epidemiology, pathology, immunology, genetics, biostatistics, bioinformatics, and data science. Since first convened in 2013, the International MPE Meeting series has grown into a dynamic and dedicated platform for experts from these disciplines to communicate novel findings, discuss new research opportunities and challenges, build professional networks, and educate the next-generation scientists. Herein, we share the proceedings of the Fifth International MPE meeting, held virtually online, on May 24 and 25, 2021. The meeting consisted of 21 presentations organized into the three main themes, which were recent integrative MPE studies, novel cancer profiling technologies, and new statistical and data science approaches. Looking forward to the near future, the meeting attendees anticipated continuous expansion and fruition of MPE research in many research fronts, particularly immune-epidemiology, mutational signatures, liquid biopsy, and health disparities.

Indexed as

NeoplasmsPathology, MolecularHumansMutationTumor MicroenvironmentImmuno-epidemiologyMeeting proceedingsMeeting reportMeeting summaryMolecular pathological epidemiology

Identifiers

PMID35759080
PMCPMC9244289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.